Hazlett Burt & Watson Inc. Has $1.02 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Hazlett Burt & Watson Inc. decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,185 shares of the medical research company’s stock after selling 68 shares during the quarter. Hazlett Burt & Watson Inc.’s holdings in Amgen were worth $1,023,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of AMGN. Strategic Financial Concepts LLC bought a new position in shares of Amgen in the second quarter worth $26,000. Hershey Financial Advisers LLC acquired a new stake in Amgen during the second quarter worth about $30,000. nVerses Capital LLC bought a new position in Amgen in the 2nd quarter valued at about $31,000. Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter valued at approximately $33,000. Finally, Matrix Trust Co bought a new stake in shares of Amgen during the 3rd quarter worth approximately $36,000. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 0.1 %

Shares of AMGN traded down $0.42 during mid-day trading on Monday, reaching $318.80. 301,645 shares of the company were exchanged, compared to its average volume of 2,408,154. The business has a 50 day simple moving average of $324.47 and a two-hundred day simple moving average of $315.90. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The stock has a market capitalization of $171.30 billion, a PE ratio of 40.87, a PEG ratio of 2.89 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.89 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter in the previous year, the company earned $4.96 EPS. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. On average, analysts predict that Amgen Inc. will post 19.45 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 2.82%. Amgen’s payout ratio is currently 115.24%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on AMGN shares. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and lifted their price objective for the company from $320.00 to $333.00 in a research note on Monday, October 14th. Royal Bank of Canada reissued an “outperform” rating and set a $362.00 price target on shares of Amgen in a report on Thursday, September 26th. Bank of America raised their price objective on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Sanford C. Bernstein began coverage on Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 target price for the company. Finally, Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research note on Monday, September 16th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $333.50.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.